1294 related articles for article (PubMed ID: 23255137)
1. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
4. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
5. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
6. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
Chung SS; Giehl N; Wu Y; Vadgama JV
Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
[TBL] [Abstract][Full Text] [Related]
7. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
8. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
[TBL] [Abstract][Full Text] [Related]
9. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
10. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.
Korkaya H; Kim GI; Davis A; Malik F; Henry NL; Ithimakin S; Quraishi AA; Tawakkol N; D'Angelo R; Paulson AK; Chung S; Luther T; Paholak HJ; Liu S; Hassan KA; Zen Q; Clouthier SG; Wicha MS
Mol Cell; 2012 Aug; 47(4):570-84. PubMed ID: 22819326
[TBL] [Abstract][Full Text] [Related]
11. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
Ithimakin S; Day KC; Malik F; Zen Q; Dawsey SJ; Bersano-Begey TF; Quraishi AA; Ignatoski KW; Daignault S; Davis A; Hall CL; Palanisamy N; Heath AN; Tawakkol N; Luther TK; Clouthier SG; Chadwick WA; Day ML; Kleer CG; Thomas DG; Hayes DF; Korkaya H; Wicha MS
Cancer Res; 2013 Mar; 73(5):1635-46. PubMed ID: 23442322
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
14. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
[TBL] [Abstract][Full Text] [Related]
15. HER2 and breast cancer stem cells: more than meets the eye.
Korkaya H; Wicha MS
Cancer Res; 2013 Jun; 73(12):3489-93. PubMed ID: 23740771
[TBL] [Abstract][Full Text] [Related]
16. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
17. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
18. Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.
Ding K; Banerjee A; Tan S; Zhao J; Zhuang Q; Li R; Qian P; Liu S; Wu ZS; Lobie PE; Zhu T
J Biol Chem; 2014 Jun; 289(23):16057-71. PubMed ID: 24737320
[TBL] [Abstract][Full Text] [Related]
19. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.
Voutsadakis IA
Clin Transl Oncol; 2019 May; 21(5):539-555. PubMed ID: 30306401
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Lesniak D; Sabri S; Xu Y; Graham K; Bhatnagar P; Suresh M; Abdulkarim B
PLoS One; 2013; 8(8):e71987. PubMed ID: 23991019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
